Early Access to Medicines Scheme (EAMS) announced for Risdiplam in the UK
17 September 2020
Today, the Medicines and Healthcare Products Regulatory Agency (MRHA) announced access to Risdiplam for those who have SMA Type 1 or Type 2, aged 2 months and older, who are not suitable for authorised treatments.
You can find the announcement on the MRHA website here.
The Patient Groups (PAGs) are jointly collating questions about the scheme and will be asking Roche to provide answers as quickly as possible. Questions, similar to the range of those asked about the Compassionate Use Programme, will include:
- Details of eligibility criteria
- How people are referred to the scheme
- What happens now to the Compassionate Use Programme (CUP)
If you have a question, please send it by Email or Facebook asap to one of the PAGs to forward.